MedTrace Logo

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

NCT02041299 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2021-08-10

Study results available
· View outcomes & findings →

Summary

This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.

Conditions

Interventions

DRUG

Deferiprone

DRUG

Deferoxamine

Sponsors & Collaborators

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • Janet Kwiatkowski, MD · Children's Hospital of Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-17
Primary Completion
2019-04-20
Completion
2019-06-18

Countries

  • United States
  • Brazil
  • Canada
  • Egypt
  • Saudi Arabia
  • Tunisia
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02041299 on ClinicalTrials.gov